Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab-Reference-Cited by-同舟云学术

Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab

Published:2020-04 Issue:4 Volume:82 Page:927-935
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Blauvelt Andrew,Shi Nianwen,Burge Russel,Malatestinic William N.,Lin Chen-Yen,Lew Carolyn R.,Zimmerman Nicole M.,Goldblum Orin M.,Zhu Baojin,Murage Mwangi J.

Funder

Eli Lilly and Company

IBM Watson Health

Publisher

Elsevier BV

Subject

Dermatology

Reference29 articles.

1. Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis;Shalom;Acta Derm Venereol,2015

2. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis;Yeung;J Am Acad Dermatol,2013

3. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis;Egeberg;Br J Dermatol,2018

4. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis;Blauvelt;J Eur Acad Dermatol Venereol,2017

5. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy;Brezinski;PLoS One,2012

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis;Drugs;2024-04-17

2. Rapid and sustained resolution in generalized pustular psoriasis with IL‐17A inhibitors required high adherence: a 96‐week analysis in a real‐life setting;International Journal of Dermatology;2024-04-17

3. Advantages of IL-17 inhibitor, ixekizumab, in the treatment of severe psoriasis;Meditsinskiy sovet = Medical Council;2024-03-08

4. Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets;Frontiers in Immunology;2024-01-04

5. Biologics protect psoriasis patients from being exacerbated by COVID-19 infection;Heliyon;2024-01